Generic drug maker Juno Pharmaceuticals and US-based Millennium Pharmaceuticals have reached an in-principle settlement in their trans-Pacific dispute over two patents covering breakthrough anti-cancer medication Velcade.
US biotechnology company Regeneron Pharmaceuticals has filed a Federal Court challenge after losing its opposition to a patent application by UK biopharmaceutical company Kymab for a method of producing an animal with part-human DNA.
The Australian federal government’s proposed legislation to abolish the innovation patent system, Australia’s second tier patent system, was introduced into parliament on July 25. Here, Griffith Hack’s Dr Malcolm Lyons and Dr Justin Sweetman tell you what you need to know about the Intellectual Property Laws Amendment (Productivity Commission Response Part 2 and Other Measures) Bill 2019.
US biotechnology firm Regeneron Pharmaceuticals has lost its opposition to a proposed patent by UK biopharmaceutical company Kymab for a method of producing an animal with part-human DNA.
A subsidiary of Coca Cola has won its bid for removal of Sunraysia Natural Beverages’ Honest Kids trade mark for non-use, with IP Australia finding only “minimal and isolated” uses of the disputed mark.
In its opening submissions in a trade mark case brought by Botox maker Allergan, Australian cosmetics brand Self Care compared its used of the word Botox to describe its alternative cosmetic products to the iPhone secondary accessories market, saying its use did not imply an affiliation with the injectable wrinkle treatment’s maker.
A case simultaneously challenging IP Australia’s decisions to accept, grant and certify an innovation patent owned by one of Australia’s biggest building product companies has been withdrawn, a court has heard.
The battle to acquire IP services company Xenith IP Group is set to intensify after the Australian Competition and Consumer Commission blessed a hostile offer by IPH Limited.
The Australian Competition and Consumer Commission will not oppose the merger of two companies that own some of Australia’s largest intellectual property boutiques.
An eight-day joint hearing in cases brought by Allergan alleging infringement of its Botox trade mark, which was due to commence Monday, has been unexpectedly vacated by the court, with barristers and legal teams left in the dark about the reasons.